BIOGEN INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- BIOGEN INC. payments for repurchase of common stock for the quarter ending 2023-12-31 was $0.00.
- BIOGEN INC. payments for repurchase of common stock for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. payments for repurchase of common stock for the quarter ending 2022-12-31 was $0.00.
- BIOGEN INC. payments for repurchase of common stock for the quarter ending 2022-09-30 was $250.00M, a 66.67% decline year-over-year.
- BIOGEN INC. payments for repurchase of common stock for fiscal 2024 was $0.00.
- BIOGEN INC. payments for repurchase of common stock for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- BIOGEN INC. payments for repurchase of common stock for fiscal 2022 was $750.00M, a 58.33% decline from fiscal 2021.
- BIOGEN INC. payments for repurchase of common stock for fiscal 2021 was $1.80B, a 73.05% decline from fiscal 2020.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-12 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $0.00 10-K · filed 2025-02-12 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $750.00M 10-K · filed 2025-02-12 |
| 2022-09-30 | $250.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $750.00M derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-06-30 | $500.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-25 | $1.25B derived: sum of 4 quarters · filed 2024-02-14 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-03 | $1.20B derived: sum of 4 quarters · filed 2024-02-14 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-14 | $1.80B 10-K · filed 2024-02-14 |
| 2021-09-30 | $750.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $2.20B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $450.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-20 | $2.70B derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | $600.00M 10-Q · filed 2022-05-03 | $5.06B derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $400.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $6.68B 10-K · filed 2023-02-15 |
| 2020-09-30 | $1.25B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-20 | $8.37B derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-06-30 | $2.81B derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-22 | $7.84B derived: sum of 4 quarters · filed 2022-02-03 |
| 2020-03-31 | $2.22B 10-Q · filed 2021-04-22 | $7.43B derived: sum of 4 quarters · filed 2022-02-03 |
| 2019-12-31 | $2.09B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-03 | $5.87B 10-K · filed 2022-02-03 |
| 2019-09-30 | $717.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-21 | $5.13B derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-06-30 | $2.40B derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-22 | $4.41B derived: sum of 4 quarters · filed 2021-02-03 |
| 2019-03-31 | $655.80M 10-Q · filed 2020-04-23 | $4.76B derived: sum of 4 quarters · filed 2021-02-03 |
| 2018-12-31 | $1.35B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-03 | $4.35B 10-K · filed 2021-02-03 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-22 | $3.00B derived: sum of 4 quarters · filed 2020-02-06 |
| 2018-06-30 | $2.75B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-24 | $3.00B derived: sum of 4 quarters · filed 2020-02-06 |
| 2018-03-31 | $250.00M 10-Q · filed 2019-04-24 | $1.03B derived: sum of 4 quarters · filed 2020-02-06 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $1.37B 10-K · filed 2020-02-06 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-23 | $2.02B derived: sum of 4 quarters · filed 2019-02-06 |
| 2017-06-30 | $781.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-07-24 | $2.37B derived: sum of 4 quarters · filed 2019-02-06 |
| 2017-03-31 | $583.60M 10-Q · filed 2018-04-24 | $1.58B derived: sum of 4 quarters · filed 2019-02-06 |
| 2016-12-31 | $651.10M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | $1.00B 10-K · filed 2019-02-06 |
| 2016-09-30 | $348.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-24 | $2.35B derived: sum of 4 quarters · filed 2018-02-01 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-25 | $4.96B derived: sum of 4 quarters · filed 2018-02-01 |
| 2016-03-31 | $0.00 10-Q · filed 2017-04-25 | |
| 2015-12-31 | $2.00B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $5.00B 10-K · filed 2018-02-01 |
| 2015-09-30 | $2.96B derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-26 | |
| 2014-12-31 | $526.82M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $886.80M 10-K · filed 2017-02-02 |
| 2014-09-30 | $23.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-21 | $359.97M derived: sum of 4 quarters · filed 2016-02-03 |
| 2014-06-30 | $336.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-24 | -$22.40M derived: sum of 4 quarters · filed 2016-02-03 |
| 2014-03-31 | $0.00 10-Q · filed 2014-04-23 | -$359.31M derived: sum of 4 quarters · filed 2016-02-03 |
| 2013-12-31 | -$8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $400.30M 10-K · filed 2016-02-03 |
| 2013-09-30 | -$359.30M 10-Q · filed 2013-10-28 | -$296.73M derived: sum of 4 quarters · filed 2015-02-04 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-23 | $115.79M derived: sum of 4 quarters · filed 2015-02-04 |
| 2013-03-31 | $41.02M 10-Q · filed 2014-04-23 | $562.57M derived: sum of 4 quarters · filed 2015-02-04 |
| 2012-12-31 | $21.54M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $984.72M 10-K · filed 2015-02-04 |
| 2012-09-30 | $53.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $1.07B derived: sum of 4 quarters · filed 2014-02-06 |
| 2012-06-30 | $446.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $1.02B derived: sum of 4 quarters · filed 2014-02-06 |
| 2012-03-31 | $463.17M 10-Q · filed 2013-04-25 | $765.86M derived: sum of 4 quarters · filed 2014-02-06 |
| 2011-12-31 | $111.40M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $497.98M 10-K · filed 2014-02-06 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-25 | $386.57M derived: sum of 4 quarters · filed 2013-02-05 |
| 2011-06-30 | $191.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-24 | $854.82M derived: sum of 4 quarters · filed 2013-02-05 |
| 2011-03-31 | $195.29M 10-Q · filed 2012-05-01 | $1.70B derived: sum of 4 quarters · filed 2013-02-05 |
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-05 | $2.08B 10-K · filed 2013-02-05 |
| 2010-09-30 | $468.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $2.77B derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-06-30 | $1.03B derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-26 | $2.30B derived: sum of 4 quarters · filed 2012-02-03 |
| 2010-03-31 | $577.58M 10-Q · filed 2011-04-21 | $1.27B derived: sum of 4 quarters · filed 2012-02-03 |
| 2009-12-31 | $693.54M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-03 | $751.17M 10-K · filed 2012-02-03 |
| 2009-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26 | $236.80M derived: sum of 4 quarters · filed 2011-02-04 |
| 2009-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-20 | $1.36B derived: sum of 4 quarters · filed 2011-02-04 |
| 2009-03-31 | $57.63M 10-Q · filed 2010-04-20 | |
| 2008-12-31 | $179.17M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-04 | $738.94M 10-K · filed 2011-02-04 |
| 2008-09-30 | $1.12B derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-21 | |
| 2007-12-31 | $2.99B 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |